{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Higher-Dose+Rifampin",
    "query": {
      "intervention": "Higher-Dose Rifampin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T23:21:19.482Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04553406",
      "title": "Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mycobacterium Avium Complex",
        "Non-tuberculous Mycobacterium Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "SPR720",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Open-label Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spero Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2020-12-03",
      "completion_date": "2021-01-28",
      "has_results": true,
      "last_update_posted_date": "2022-02-28",
      "last_synced_at": "2026-09-17T23:21:19.482Z",
      "location_count": 9,
      "location_summary": "Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more",
      "locations": [
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04553406"
    },
    {
      "nct_id": "NCT03301038",
      "title": "Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Infantile Hypercalcaemia - Severe Form",
        "Genetic Disease",
        "Hypercalcemia, Idiopathic, of Infancy",
        "Hypercalciuric Hypercalcemia",
        "Idiopathic Infantile Hypercalcemia - Mild Form",
        "Hypercalciuria"
      ],
      "interventions": [
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "6 Months to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2018-07-25",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-09-17T23:21:19.482Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03301038"
    },
    {
      "nct_id": "NCT01349192",
      "title": "Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Methicillin-resistant Staphylococcus Aureus"
      ],
      "interventions": [
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Trimethoprim/Sulfamethoxazole",
          "type": "DRUG"
        },
        {
          "name": "Minocycline",
          "type": "DRUG"
        },
        {
          "name": "Mupirocin",
          "type": "DRUG"
        },
        {
          "name": "chlorhexidine gluconate oral rinse",
          "type": "DRUG"
        },
        {
          "name": "2% Chlorhexidine solution wipes",
          "type": "DRUG"
        },
        {
          "name": "Environmental Decontamination",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "4 Years to 45 Years"
      },
      "enrollment_count": 47,
      "start_date": "2011-04",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-09-17T23:21:19.482Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Aurora, Colorado • Gainesville, Florida + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349192"
    },
    {
      "nct_id": "NCT01218620",
      "title": "Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Gamma-Secretase Inhibitor RO4929097",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Midazolam Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Tolbutamide",
          "type": "DRUG"
        },
        {
          "name": "Dextromethorphan Hydrobromide",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2010-09",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2014-12-23",
      "last_synced_at": "2026-09-17T23:21:19.482Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01218620"
    },
    {
      "nct_id": "NCT00042289",
      "title": "Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "atazanavir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #3",
          "type": "DRUG"
        },
        {
          "name": "elvitegravir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "tenofovir alafenamide fumarate (TAF)",
          "type": "DRUG"
        },
        {
          "name": "TAF w/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "TAF w/cobicistat or ritonavir",
          "type": "DRUG"
        },
        {
          "name": "efavirenz",
          "type": "DRUG"
        },
        {
          "name": "darunavir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir/tenofovir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "rifampicin",
          "type": "DRUG"
        },
        {
          "name": "ethambutol",
          "type": "DRUG"
        },
        {
          "name": "isoniazid",
          "type": "DRUG"
        },
        {
          "name": "pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "kanamycin",
          "type": "DRUG"
        },
        {
          "name": "amikacin",
          "type": "DRUG"
        },
        {
          "name": "capreomycin",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "levoflaxacin",
          "type": "DRUG"
        },
        {
          "name": "ofloxacin",
          "type": "DRUG"
        },
        {
          "name": "ethionamide/prothionamide",
          "type": "DRUG"
        },
        {
          "name": "terizidone/cycloserine",
          "type": "DRUG"
        },
        {
          "name": "para-aminosalicylic acid (PAS)",
          "type": "DRUG"
        },
        {
          "name": "high dose INH",
          "type": "DRUG"
        },
        {
          "name": "bedaquiline",
          "type": "DRUG"
        },
        {
          "name": "clofazamine",
          "type": "DRUG"
        },
        {
          "name": "delamanid",
          "type": "DRUG"
        },
        {
          "name": "linezolid",
          "type": "DRUG"
        },
        {
          "name": "pretomanid",
          "type": "DRUG"
        },
        {
          "name": "ethinyl estradiol",
          "type": "DRUG"
        },
        {
          "name": "etonogestrel implant",
          "type": "DRUG"
        },
        {
          "name": "nevirapine",
          "type": "DRUG"
        },
        {
          "name": "amprenavir",
          "type": "DRUG"
        },
        {
          "name": "abacavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "indinavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "fosamprenavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #3",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "didanosine delayed release (Videx® EC)",
          "type": "DRUG"
        },
        {
          "name": "emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "tenofovir",
          "type": "DRUG"
        },
        {
          "name": "nelfinavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "tipranavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #4",
          "type": "DRUG"
        },
        {
          "name": "raltegravir",
          "type": "DRUG"
        },
        {
          "name": "etravirine",
          "type": "DRUG"
        },
        {
          "name": "maraviroc",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "tenofovir/atazanavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "nelfinavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "indinavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1578,
      "start_date": "2003-06-09",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-09-17T23:21:19.482Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042289"
    },
    {
      "nct_id": "NCT04118842",
      "title": "A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Savolitinib",
          "type": "DRUG"
        },
        {
          "name": "Rifampicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2019-10-17",
      "completion_date": "2020-02-26",
      "has_results": false,
      "last_update_posted_date": "2020-04-03",
      "last_synced_at": "2026-09-17T23:21:19.482Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04118842"
    },
    {
      "nct_id": "NCT01408914",
      "title": "Trial of High-Dose Rifampin in Patients With TB",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Higher-Dose Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harvard University Faculty of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 180,
      "start_date": "2013-09",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-11-20",
      "last_synced_at": "2026-09-17T23:21:19.482Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01408914"
    },
    {
      "nct_id": "NCT02563327",
      "title": "Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Rifapentine",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid",
          "type": "DRUG"
        },
        {
          "name": "Pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "Ethambutol",
          "type": "DRUG"
        },
        {
          "name": "Pyridoxine",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2516,
      "start_date": "2016-01-25",
      "completion_date": "2021-08-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-17T23:21:19.482Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02563327"
    },
    {
      "nct_id": "NCT01845298",
      "title": "Immune Activation and Drug Absorption in HIV-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Rifampicin 600 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Drexel University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 7,
      "start_date": "2014-06",
      "completion_date": "2016-03-14",
      "has_results": false,
      "last_update_posted_date": "2017-03-03",
      "last_synced_at": "2026-09-17T23:21:19.482Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01845298"
    }
  ]
}